In this task, you are provided with an article of the legal acts. Your task is to classify it into three categories (Regulation, Decision and Directive) based on its content: 1) Regulation is a binding legislative act that must be applied in its entirety on a set date across all the member states (European Union countries). 2) Decision is binding on those to whom it is addressed (e.g. an European Union country or an individual company) and is directly applicable. 3) Directive is a legislative act that sets out a goal that all  must achieve. However, it is up to the individual countries to devise their own laws on how to reach these goals.

[EX Q]: Directive 65/65/EEC is hereby amended as follows:1. Point 8 of the second paragraph of Article 4 shall be replaced by the following text:'8. Results of:- physico-chemical, biological or microbiological tests,- pharmacological and toxicological tests,- clinical trials.However, and without prejudice to the law relating to the protection of industrial and commercial property:(a) The applicant shall not be required to provide the results of pharmacological and toxicological tests or the results of clinical trials if he can demonstrate:(i) either that the proprietary medicinal product is essentially similar to a product authorized in the country concerned by the application and that the person responsible for the marketing of the original proprietary medicinal product has consented to the pharmacological, toxicological or clinical references contained in the file on the original proprietary medicinal product being used for the purpose of examining the application in question;(ii) or by detailed references to published scientific literature presented in accordance with the second paragraph of Article 1 of Directive 75/318/EEC that the constituent or constituents of the proprietary medicinal product have a well established medicinal use, with recognized efficacy and an acceptable level of safety;(iii) or that the proprietary medicinal product is essentially similar to a product which has been authorized within the Community, in accordance with Community provisions in force, for not less than six years and is marketed in the Member State for which the application is made; this period shall be extended to 10 years in the case of high-technology medicinal products within the meaning of Part A in the Annex to Directive 87/22/EEC (1) or of a medicinal product within the meaning of Part B in the Annex to that Directive for which the procedure laid down in Article 2 thereof has been followed; furthermore, a Member State may also extend this period to 10 years by a single Decision covering all the products marketed on its territory where it considers this necessary in the interest of public health. Member States are at liberty not to apply the abovementioned six-year period beyond the date of expiry of a patent protecting the original product.However, where the proprietary medicinal product is intended for a different therapeutic use from that of the other proprietary medicinal products marketed or is to be administered by different routes or in different doses, the results of appropriate pharmacological and toxicological tests and/or of appropriate clinical trials must be provided.(b) In the case of new proprietary medicinal products containing known constituents not hitherto used in combination for therapeutic purposes, the results of pharmacological and toxicological tests and of clinical trials relating to that combination must be provided, but it shall not be necessary to provide references relating to each individual constituent.(1) OJ No L 15, 17. 1. 1987, p. 38.';2. Article 16 is hereby repealed. Member States shall take the measures necessary to comply with this Directive no later than 1 July 1987. They shall forthwith inform the Commission thereof.However, with regard to the Hellenic Republic, the Kingdom of Spain and the Portuguese Republic, the date referred to in the first paragraph shall be replaced by 1 January 1992. This Directive is addressed to the Member States.
[EX A]: Directive

[EX Q]: The Annex to Directive 74/63/EEC is amended as follows:1. In part A 'Substances (ions or elements)', the text of item 4 'Mercury' is replaced by the following:1.2.3 //   //   //   // Substances, products  // Feedingstuffs  // Maximum content in mg/kg (ppm) of feedingstuff, at a moisture content of 12 % (a)  //   //   //  // 4. Mercury  // Straight feedingstuffs with the exception of:  // 0,1  //   // - feedingstuffs produced by the processing of fish or other marine animals  // 0,5  //   // Complete feedingstuffs with the exception of:  // 0,1  //   // - complete feedingstuffs for dogs and cats  // 0,4  //   //   //2. In part B 'Products', against item 1 'Aflatoxin B1', the figure '0,02' shown in the column headed 'Maximum content in mg/kg (ppm) of unadulterated matter' opposite 'Complementary feedingstuffs for dairy cattle' is replaced by the figure '0,01'. The Member States shall bring into force, on 31 December 1983 at the latest, the laws, regulations and administrative provisions necessary to comply with Article 1. They shall forthwith inform the Commission thereof. This Directive is addressed to the Member States.
[EX A]: Directive

[EX Q]: The Agreement in the form of an exchange of letters amending Tables I and II annexed to Protocol 2 to the Agreement between the European Economic Community and the Swiss Confederation is hereby approved on behalf of the Community.The text of the Agreement is annexed to this Regulation. The President of the Council is hereby authorized to appoint the person empowered to sign the Agreement for the purpose of binding the Community. This Regulation shall enter into force on the day following its publication in the Official Journal of the European Communities.This Regulation shall be binding in its entirety and directly applicable in all Member States.
[EX A]:
Regulation